Redmile Group LLC Reduces Position in ProQR Therapeutics N.V. (PRQR)

Redmile Group LLC cut its position in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,553,225 shares of the biopharmaceutical company’s stock after selling 24,949 shares during the period. Redmile Group LLC owned about 6.65% of ProQR Therapeutics N.V. worth $7,766,000 as of its most recent SEC filing.

Separately, Hikari Power Ltd bought a new stake in ProQR Therapeutics N.V. during the first quarter valued at about $121,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Institutional Ownership by Quarter for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) traded up 1.02% during trading on Tuesday, reaching $4.95. The company’s stock had a trading volume of 23,448 shares. The firm’s market cap is $118.13 million. ProQR Therapeutics N.V. has a 12 month low of $3.65 and a 12 month high of $8.70. The stock’s 50 day moving average price is $5.02 and its 200-day moving average price is $4.62.

ProQR Therapeutics N.V. (NASDAQ:PRQR) last posted its earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.02. Equities analysts predict that ProQR Therapeutics N.V. will post ($2.14) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

Several analysts recently issued reports on the company. Zacks Investment Research upgraded ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a report on Wednesday, May 3rd. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of ProQR Therapeutics N.V. in a report on Tuesday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.05.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply